A randomized, double‐blind, placebo‐controlled study on long‐term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long‐Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 2, 2015-02 ,pp. : 152-160

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16‐week, randomized, placebo‐controlled trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 699-702

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double‐blind, parallel‐group, comparative study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 12, 2015-12 ,pp. : 1198-1201

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study

By Williams-Herman Debora   Johnson Jeremy   Teng Rujun   Luo Edmund   Davies Michael J.   Kaufman Keith D.   Goldstein Barry J.   Amatruda John M.  

Current Medical Research and Opinion, Vol. 25, Iss. 3, 2009-03 ,pp. : 569-583

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study

By Seino Yutaka   Fujita Tetsuya   Hiroi Shinzo   Hirayama Masashi   Kaku Kohei  

Current Medical Research and Opinion, Vol. 27, Iss. 9, 2011-09 ,pp. : 1781-1792

Informa Healthcare

Access to resources Recommend Favorite